DLBCL is a type of blood cancer that can be tough to treat. It stands for diffuse large B-cell lymphoma. The introduction of CAR-T therapy has been a game-changer for patients with relapsed or refractory DLBCL. CAR-T therapy is a type of treatment that uses a patient's own immune cells to fight cancer. It was first approved by the FDA in 2017. But how has this ne...

In Uganda, people with diffuse large B-cell lymphoma (DLBCL) face a tougher fight than those in wealthier nations. The main reason is that they do not have the same access to treatments. One treatment that has shown to improve survival rates is a combination of rituximab and chemotherapy. Rituximab is a drug that targets and destroys certain cells in the body. Ho...

Imagine if cancer treatments could be more like a guided missile, hitting only the bad guys while leaving healthy cells unharmed. That's the idea behind antibody-drug conjugates (ADCs), which are revolutionizing the way we fight certain cancers, including diffuse large B-cell lymphoma (DLBCL). An ADC is like a tiny, smart bomb. It's made up of three parts: a monoclo...